Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 September 2012
|
| In: |
BMC cancer
Year: 2012, Jahrgang: 12 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-12-438 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-438 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1471-2407-12-438 
|
| Verfasserangaben: | Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581880634 | ||
| 003 | DE-627 | ||
| 005 | 20220815031050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181015s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1471-2407-12-438 |2 doi | |
| 035 | |a (DE-627)1581880634 | ||
| 035 | |a (DE-576)511880634 | ||
| 035 | |a (DE-599)BSZ511880634 | ||
| 035 | |a (OCoLC)1341019993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Thaler, Josef |e VerfasserIn |0 (DE-588)1169057624 |0 (DE-627)1032698888 |0 (DE-576)51188107X |4 aut | |
| 245 | 1 | 0 | |a Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study |c Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne |
| 264 | 1 | |c 29 September 2012 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.10.2018 | ||
| 520 | |a Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. | ||
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 12(2012), Artikel-ID 438 |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study |
| 773 | 1 | 8 | |g volume:12 |g year:2012 |g elocationid:438 |g extent:10 |a Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/1471-2407-12-438 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/1471-2407-12-438 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181015 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 6 | ||
| 999 | |a KXP-PPN1581880634 |e 3028702061 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Thaler","display":"Thaler, Josef","given":"Josef","role":"aut"},{"display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut","family":"Hofheinz"}],"name":{"displayForm":["Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne"]},"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"id":{"doi":["10.1186/1471-2407-12-438"],"eki":["1581880634"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2001","publisher":"BioMed Central ; Springer","dateIssuedDisp":"2001-","publisherPlace":"London ; Berlin ; Heidelberg"}],"recId":"326643710","id":{"zdb":["2041352-X"],"issn":["1471-2407"],"eki":["326643710"]},"disp":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyBMC cancer","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 22.05.20"],"pubHistory":["1.2001 -"],"title":[{"title":"BMC cancer","title_sort":"BMC cancer"}],"language":["eng"],"part":{"extent":"10","volume":"12","year":"2012","text":"12(2012), Artikel-ID 438"}}],"note":["Gesehen am 15.10.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"29 September 2012","dateIssuedKey":"2012"}],"recId":"1581880634","title":[{"title":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study","title_sort":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study"}],"language":["eng"]} | ||
| SRT | |a THALERJOSESKINTOXICI2920 | ||